NSW Health Expands SOZO® Use for Lymphoedema Prevention

**Brisbane, Australia** – ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced that New South Wales (NSW) Health is expanding its use of the SOZO® Digital Health Platform for lymphoedema prevention. NSW Health is purchasing up to eight additional SOZO devices to grow its Lymphoedema Prevention Program for cancer patients.

With the addition of these new devices, NSW Health will more than double the number of SOZO devices in use under its Lymphoedema Prevention Program. Five of these devices will be deployed in the Western NSW Local Health District (LHD) of NSW Health.

“At New South Wales Health, we are working to increase survival and quality of life for people with cancer,” said Ruth Jones, Director of Cancer Services and Innovation for Western NSW LHD of NSW Health. “The SOZO technology and lymphoedema prevention model-of-care align well with our goals of improving patient care while decreasing costs associated with chronic lymphoedema treatment. We have begun to see the benefits for patients using SOZO and, with these new devices, this will expand access to patients in a range of areas within the LHD.”

NSW Health operates over 230 public hospitals in its eight local districts that cover the Sydney metropolitan region and surrounding rural areas. With nearly 45,000 new cancer cases every year, NSW is the largest public health system in Australia. As a connected health platform, SOZO allows patients and their care providers to access their lymphoedema measurements at every location in the NSW Health network.

“The experience at New South Wales Health demonstrates a successful approach for building lymphoedema prevention programs,” said Richard Carreon, Managing Director and CEO of ImpediMed. “By beginning at a small number of select sites, they were able to establish a robust program from which to expand across the health system. Now, fewer patients will have to endure the pain and hardship of living with chronic lymphoedema as well as its high cost treatments.”

The Lymphoedema Prevention Program utilises ImpediMed's Test, Trigger, Treat™ protocol for early detection and intervention of cancer-related lymphoedema. Routine lymphoedema testing of cancer survivors uses the company's SOZO device with BIS (L-Dex®) technology. A significant increase in a patient's L-Dex score is a trigger to evaluate the patient and initiate intervention. ImpediMed's PREVENT Trial, the largest multi-site, randomised controlled trial ever performed to study lymphoedema prevention, showed that this protocol resulted in a 95% reduction in lymphoedema progression at one year.

The aim of the Lymphoedema Prevention Program is to help educate healthcare providers and patients that with the proper protocols in place, lymphoedema can be detected and managed before it becomes a debilitating chronic condition. Learn more at [www.preventlymphedema.com](http://www.preventlymphedema.com).
Contact Details

Investor Relations Contact: Mike Bassett, ImpediMed
T: +61 407 431 432
E: mbassett@impedimed.com

Media Contact: Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@we-worldwide.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.